Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/publications/9297-cost-effectiveness-of-pembrolizumab-vs-chemotherapy-as-first-line-treatment-for-metastatic-nsclc-that-expresses-high-levels-of-pd-l1-in-switzerland/authors